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Abstract: Over the past decade, vulnerability- and psychosis-associated structural and functional brain abnormalities in a population at 
high clinical risk to develop psychosis were intensively studied. We reviewed the results from studies comparing at-risk mental state 
(ARMS) individuals with and without subsequent transition to psychosis. Additionally, we introduced a new concept of splitting ARMS 
population according to the duration of the psychosis risk syndrome and their probability to develop psychosis. Studying the ARMS indi-
viduals still vulnerable to psychosis but with lower risk to transit can disclose the possible protective – resilience factors or characteris-
tics. Resilience, understood as ability to recover from change, can be thus applied in the early intervention for high clinical risk for psy-
chosis individuals. 
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1. THE PRODROMAL STAGE OF PSYCHOSIS  
 The research in the prodromal stages of serious physical dis-
eases, e.g. cardiovascular and oncological diseases, has exponen-
tially progressed. Similarly, over the last decades early clinical 
detection and intervention in patients with psychoses have become 
widespread.  Psychosis seems to be preventable or at least success-
fully treatable in the early stages before frank psychosis breakdown 
[1, 2]. Early detection services worldwide [3-5] identify individuals, 
who are experiencing prodromal symptoms characterized by at-
tenuated psychotic symptoms, or brief limited psychotic symptoms 
or a decline in social and/or occupational functioning. They are 
broadly termed as having a clinical high-risk or an ‘at risk mental 
state’ (ARMS) (for review see [6]), more recently as the ‘Psychosis 
Risk Syndrome’ [7]. Research in early and prodromal phases of the 
illness may provide important findings on etiology that are not 
confounded by medication and/or chronicity related effects. 
 The developing psychosis is understood as a continuum with 
early mild clinical signs [6, 8-10]. A high-risk state of psychosis 
may be a consequence of a genetic predisposition [11] and/or gene-
neurodevelopmental interaction [12-14] and/or other stress factors 
[15] leading to the increased clinical risk for psychosis. Around 15-
40% [2, 3, 5, 13, 16] of these high-risk individuals go on to develop 
psychosis with more severe symptoms and some of them continue 
to a serious chronic disease. Research has attempted to identify 
definitive markers that distinguish those, who go on to develop 
psychosis from those, who do not. However, it is difficult to iden-
tify the individuals, who will later develop psychosis solely on 
clinical or symptomatic grounds. Therefore, we are facing the need 
to additionally characterize vulnerability- and resilience-associated 
neurobiological markers. Neuroimaging methods help to clarify the 
mechanisms underlying psychosis, as the same individuals can be 
studied before and after the onset of frank psychosis, often with 
only minimal confounding effects of the previous treatment. 
 The term ‘at-risk mental state’ (ARMS) has been suggested as a 
replacement of the term ‘prodromal’, to delineate a subthreshold 
syndrome that confers high – but not inevitable – risk for develop-
ment of psychotic disorder in the near future [5]. The ARMS is 
defined according to the PACE (Personal Assessment and Crisis 
Evaluation Clinic, Melbourne) criteria and requires individuals to  
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present a) attenuated positive psychotic or b) brief limited intermit-
tent symptoms that do not reach the threshold of frank psychosis or 
c) functional decline and genetic risk [3, 16, 17]. These psycho-
pathological symptoms are often associated with negative symp-
toms [3, 9] and subtle cognitive deficits [3, 18-20]. Furthermore, 
neurofunctional deficits may be associated with transition to psy-
chosis and thus can be seen as vulnerability markers for developing 
frank psychosis [3, 21].  
2. NEUROIMAGING FINDINGS IN PSYCHOSIS 
 Postmortem [22, 23] as well as neuroimaging studies described 
brain structural deficits of patients suffering from psychosis [24]. 
The most replicated and pronounced findings are increase of ven-
tricular volumes and reduction of total gray matter, white matter 
and whole brain volume [25-27]. Meta-analyses of voxel based 
morphometry studies in schizophrenia have shown additional re-
gional gray matter volume (GMV) reduction in the anterior cingu-
late, insula, medial prefrontal and temporal cortex, in the thalamic 
and other subcortical regions [28-31]. In first-episode patients, 
hippocampal, thalamic, insular and cingulate cortex reductions are 
involved [32]. More extensive reductions in medial and dorsolateral 
prefrontal cortex and in the superior temporal gyrus have been 
observed in chronic schizophrenia [32]. A number of confounding 
factors may influence the heterogeneity across imaging findings 
[33, 34], in particular antipsychotic medication may play a promi-
nent role [35]. However, conflicting results across studies prevent 
applicability of imaging methods in clinical psychiatry.Some of the 
brain structural abnormalities have been characterized as trait fac-
tors, known to be present in relatives of schizophrenia patients [36, 
37].Other disease-related abnormalities seem to be state markers, 
i.e. markers of very early stages (high clinical risk for psychosis), of 
transition to full-blown psychosis or of chronic disease. Pantelis et 
al. described acceleration of gray matter reduction specifically in 
prefrontal region in first-episode patients, prodromal patients and 
high-risk individuals [12]. Not only abnormalities in the brain 
network, but also reduced connectivity between distinct brain re-
gions appear to apply across all stages of schizophrenia [38]. 
 On the other hand, several neurofunctional abnormalities have 
been described in patients suffering from psychosis. Executive 
function impairments including working memory (WM) [39-47], 
spatial memory and verbal fluency deficits [48-55], and reward and 
salience processing anomalies [56-59] are pronounced cognitive 
features found in schizophrenia. However, the relation of physio-
logical and clinical variables (positive, negative symptoms) is 
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complicated by the multidimensional nature of psychotic symp-
toms. Using specific functional paradigms, individuals suffering 
from schizophrenia manifested failure of some brain regions to 
activate to a task while other regions were over-activated [60]. 
3. STRUCTURAL AND NEUROFUNCTIONAL BRAIN-
IMAGING FINDINGS IN ARMS 
 Over the past decade, structural magnetic resonance imaging 
(MRI) methods have been extensively employed to identify neuro-
anatomical alterations in the pre-psychotic phases. Several tech-
niques were implemented to investigate structural differences in 
ARMS individuals: voxel-based morphometry for gray [61-63] and 
white matter [64], region-of-interest analyses of hippocampal, 
cingulate and pituitary areas [65-73], cortical thickness [74]  and 
pattern matching [75, 76], and gyrification index [77]. Overall, in 
subjects at high-risk for psychosis with subsequent transition to 
psychosis, as compared to the high-risk individuals without subse-
quent transition, MRI studies showed volumetric reductions in 
frontal, insular, cingulate, lateral and middle temporal, and cerebel-
lar regions [13, 61-63, 66, 71, 75, 76, 78, 79]. These regions are 
similar to the regions of structural deficits found in first-episode 
schizophrenia [80-84] and in the relatives of schizophrenia patients 
[85, 86]. The latter indicates that the volumetric reductions in these 
regions are not only affected in prodromal or manifest psychosis 
but also represent potential vulnerability markers for the illness. 
Recent advances in psychiatric research indicate that neurocogni-
tive deficits are also evident in subjects with an at-risk mental state 
(ARMS) [19, 87-90] and in non-affected first-degree relatives [91-
96].  
 Functional MRI studies are based on known impaired cognitive 
domains in the early stages of schizophrenic psychosis. They use an 
‘activation paradigm’, which engages the brain region/s of interest 
and the results reflect abnormalities in these specific cognitive 
domains.  Some of the published fMRI and multimodal functional 
studies investigated neurofunctional abnormalities in ARMS [97-
99] and found deficits in the frontal and temporal task-related net-
works [100, 101]. Several studies focused on functional deficits, 
while performing a working memory task [20, 97, 102, 103]. Such 
alterations cannot be attributed to the effects of illness or treatment 
and may represent markers of vulnerability to psychosis [100]. 
4. RESILIENCE FACTORS AND CLINICAL STAGING OF 
THE ARMS 
 Importantly, 90% of the ARMS individuals who made a transi-
tion to frank psychosis (ARMS-T) did this during the first two years 
after ascertainment [3]. After these two years, only further 3% of all 
included ARMS individuals developed frank psychosis, represent-
ing a 10-fold lower risk for transition as compared to the first two 
years after ascertainment (36% probability to transit) [3]. Similarly, 
a study by Yung confirmed that the vast majority of transitions 
occurred in the first two years (estimated hazard ratio 0.58) and 
significantly dropped over time (estimated hazard ratio 0.07) [104]. 
 Some recent studies aiming to improve individual risk assess-
ment showed that transition rate was declining over the past years 
[105, 106]. During the first two years, the transition rate declined 
from 31% published in 2003 [79] to 16% published five years later 
in a high-risk population [107]. The reasons for this decline are not 
completely clear. Most probably, individuals are more readily 
referred to early detection clinics than 10 years ago. Those identi-
fied as “at risk” might be less severely ill and therefore have a 
lower risk to rapid deterioration. Furthermore, the decline might be 
a result of non-pharmacological interventions, such as psychosocial 
intervention, family support, cognitive behavioral therapy (CBT) or 
other unknown (possibly protective) factors. Some ARMS indi-
viduals may have better internal resources, attitudinal approaches 
and overall functioning as seen by non-medicated schizophrenia 
patients [108]. They may recover subsequently [109]. Other indi-
viduals may be on the ARMS continuum for a longer period of 
time. The longer the subclinical psychosis persists in the general 
population over time, the greater the risk of transition to clinical 
psychosis as shown in a recently published 8–year cohort study 
[110]. 
 A worldwide-accepted clinical staging model of psychotic 
disorders [1, 2] describes stages of ongoing psychosis with its 
characteristics and recommended treatment. Interventions accord-
ing to the model should lead to prevention or delay of progression 
from earlier to later stages of disorder, and they should be chosen 
on a careful risk/benefit analysis [2, 111]. This approach can enable 
us to allocate each individual according to his/her deficits or ab-
normalities and to provide accurate intervention.  
 We postulate that those ARMS individuals, who are more 
vulnerable to transition and therefore have a higher probability for 
transition to psychosis, have less resilience factors and vice versa. 
Therefore, we suggest splitting the individuals with an ARMS 
according to the duration of their ARMS as well as according to 
their clinical outcome (Fig. 1). The first criterion focuses on the 
time span of risk: the short-term ARMS (ARMS-ST) group consists 
of ARMS individuals in a period shorter than two years after ascer-
tainment; individuals, who are in ARMS continuum longer than 
two years belong to the second group (long-term ARMS, ARMS-
LT). ARMS-LT individuals might represent a group with a vulner-
ability to psychosis but a relatively moderate or low transition 
probability [3]. All of the ARMS (ARMS-ST and ARMS-LT) still 
have to meet the PACE criteria and have not recovered in the mean-
time. According to the clinical outcomes ARMS individuals with 
subsequent transition to psychosis belong to the ARMS-T group. 
There were published several studies comparing ARMS-T and 
ARMS-NT (ARMS with no transition to psychosis) individuals (for 
review see [30]). ARMS-ST subjects are vulnerable to psychosis 
and we expect that around 30% out of them will transit (ARMS-T) 
in next two years, leaving still 70% of ARMS without transition to 
psychosis (ARMS-NT). The latter are of high clinical and research 
relevance and may be called ARMS-LT. We suggest following 
them longitudinally with the aim to investigate the course of their 
symptomatology and functioning as well as resilience factors pro-
tecting them from developing frank psychosis.  
 Thus the two ARMS subgroups (ARMS-ST and ARMS-LT) 
represent vulnerability groups to psychosis with different probabili-
ties of later transition to psychosis. The ARMS-LT group might 
either recover, or develop psychosis or other disease, or remain on 
the risk continuum to develop psychosis. Still, according to the 
published data the ARMS-LT group has lower probability to de-
velop subsequent psychosis than ARMS-ST. This interesting group 
could help us to define resilience factors in the at-risk mental state. 
 The spectrum of subsequent diagnoses and possible comorbid 
symptoms remains broad and worth to be studied further. Longitu-
dinally followed-up groups of ARMS without transition give us an 
opportunity to better understand the trajectory of the disease proc-
ess, when the vulnerability to transit is not subsequently followed 
by transition and when these ARMS individuals stay somehow 
protected. We are aware of inhomogeneity of this group and expect 
to detect broad spectrum of diagnoses or comorbid symptoms in a 
future. But probably, we can learn from these subjects, how to cope 
with their higher vulnerability to psychosis and still stay without 
transition. 
5. NEUROIMAGING AND STAGING OF THE RISK FOR 
PSYCHOSIS 
 As shown in our recently published meta-analysis of neuroi-
maging predictors [30], there are known structural and neurofunc-
tional deficits in ARMS individuals with subsequent transition 
(ARMS-T) as compared to the ARMS individuals without transi-
tion (ARMS-NT; see Table 1 summarizing data published in [30]). 
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 Later development of psychosis was associated with less GMV 
in the right insula, inferior frontal, and superior temporal gyrus 
[13]. Multimodal imaging analysis of structural and functional MRI 
during working memory showed association between BOLD re-
sponse and gray matter in the right insula and middle temporal 
gyrus in all ARMS individuals [112]. ARMS-ST group had deficits 
similar to the ARMS-T group as showed our study comparing 
volumetric data of ARMS-ST and ARMS-LT groups [113]. Even 
more, these insular volumetric abnormalities correlated with clini-
cal symptoms of psychosis [113]. The structural abnormalities in 
insular region have been described in individuals with impaired 
insight to the disease [114]. Positive relationship to the recovery 
and awareness of their abnormal experiences can be associated with 
increase in insular volume [115].   
 ARMS-LT with vulnerability to psychosis but lower transition 
probability might help us to find resilience-associated changes in 
their brain structure and function. We argue that ARMS-ST and 
ARMS-LT subgroups may contribute to the existing clinical staging 
model of psychosis. 
6. CONCLUSIONS 
 Neuroimaging methods might in future contribute to the predic-
tion of the probability for transition to psychosis and regarding the 
time course of illness. To be able to predict transition to psychosis 
as exactly as possible we should combine multimodal imaging 
approach with clinical symptoms and neurocognitive measures. In 
future, by improving the understanding of emerging psychosis, we 
may be able to selectively treat those patients with the highest risk 
Fig. (1). ARMS population vulnerable to psychosis with descending transition probability in a time course of their at-risk state. 
ARMS individuals can be divided according to the duration of their at-risk mental state into ARMS-ST (ARMS short-term) and ARMS-LT (ARMS long-term) 
individuals. ARMS individuals with subsequent transition to psychosis (ARMS-T) continue to first episode of psychosis (FE). ARMS-LT can be followed-up 
clinically and investigated for their vulnerability- and resilience-associated factors. 
Table 1. Meta-analysis of volumetric and functional differences between ARMS-T and ARMS-NT (Modified from [30]) 
Cohen’s d (number of studies)* 
Volumetric Abnormalities Functional Abnormalities ARMS-ST vs. ARMS-LT / 
Region 
Increased GMV Decreased  No Change Decreased 
BOLD 
NAA/Cho Decreased 5HT BP 
Temporal cortex 0.1–0.8 (4) 0.3 (7) (2) - Increased 1.0 (1) - 
Cingulate cortex - 0.4-0.9 (4) (2) (1) Decreased (1) -
Prefrontal cortex 0.5 (1) 0.1-0.9 (10) - 0.6 (1) - 1.5 (1) 
Cerebellum - (3) - - - - 
Occipital lobe - - - (1) - -
* Numbers belonging to the affected brain region characterize range of effect size calculated as Cohen’s d with the number of included studies in parentheses. 
When there is no Cohen’s d, the effect size was not possible to calculate. 
Abbreviations: 
ARMS-NT - at-risk mental state without transition, ARMS-T - at-risk mental state with transition, BOLD – bold oxygen level dependency (fMRI parameter), 
NAA/Cho – N-acetylaspartate/cholin containing compounds (MRS parameter), 5HT BP – serotonin binding potential (PET parameter) 






	

AR
ARMS-S

MS po



T
	

pulat
	

ion
	
ARMS-LT
ARMS-T
	

? transiti
? other d
? recover

on
isease
y
FE
Neuroimaging and Resilience Factors - Staging of the At-risk Mental State? Current Pharmaceutical Design, 2012, Vol. 18, No. 4    419
for psychosis. The treatment will be thus more efficient, selectively 
targeted and can integrate resilience-based non-pharmacological 
interventions to clinical psychiatry.  
ABBREVIATIONS 
ARMS = At-risk mental state 
ARMS-LT = At-risk mental state long term 
ARMS-NT = At-risk mental state without transition 
ARMS-ST = At-risk mental state short term 
ARMS-T = At-risk mental state with transition 
CBT = Cognitive behavioral therapy 
fMRI = Functional magnetic resonance imaging 
GMV = Gray matter volume 
MRS = Magnetic resonance spectroscopy 
PACE = Personal Assessment and Crisis Evaluation 
Clinic 
PET = Positron emission tomography 
sMRI = Structural magnetic resonance imaging 
WM = Working memory 
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